Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.